Creating drugs that target cancer without side effects
Improving drug design to eliminate side effects: From computational to animal models
['FUNDING_OTHER'] · PENNSYLVANIA STATE UNIVERSITY, THE · NIH-10472846
This study is looking at how to create better cancer drugs by understanding how they work with certain proteins in the body, which could help make treatments safer and more effective for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PENNSYLVANIA STATE UNIVERSITY, THE (nih funded) |
| Locations | 1 site (UNIVERSITY PARK, UNITED STATES) |
| Trial ID | NIH-10472846 on ClinicalTrials.gov |
What this research studies
This research aims to improve drug design by focusing on nuclear receptors, which are important targets in cancer treatment. The approach combines advanced computational methods and animal models to understand how these drugs interact with specific proteins that influence gene expression. By identifying the mechanisms that lead to unwanted side effects, the research seeks to develop more selective drugs that minimize harm while effectively treating cancer. Patients may benefit from safer and more effective cancer therapies as a result of this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are currently treated with drugs targeting nuclear receptors.
Not a fit: Patients with cancers that do not involve nuclear receptors or those who are not undergoing treatment for cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to cancer treatments that have fewer side effects, improving patient quality of life.
How similar studies have performed: Other research has shown promise in improving drug selectivity and reducing side effects, indicating that this approach has potential for success.
Where this research is happening
UNIVERSITY PARK, UNITED STATES
- PENNSYLVANIA STATE UNIVERSITY, THE — UNIVERSITY PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OKAFOR, C. DENISE — PENNSYLVANIA STATE UNIVERSITY, THE
- Study coordinator: OKAFOR, C. DENISE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer, Disease, Disorder